Corcept Therapeutics (CORT) News Today $60.78 +1.36 (+2.29%) (As of 12/6/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Janus Henderson Group PLC Sells 17,793 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)Janus Henderson Group PLC trimmed its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 5.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 324,017 shares of the biotechnology company'sDecember 8 at 4:24 AM | marketbeat.comPositive Outlook for Corcept Therapeutics Amid Phase III Delays and Market Opportunities for RelacorilantDecember 7 at 7:02 AM | markets.businessinsider.comPiper Sandler Sticks to Their Buy Rating for Corcept Therapeutics (CORT)December 7 at 7:02 AM | markets.businessinsider.comFmr LLC Has $63.12 Million Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Fmr LLC increased its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 24.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,363,922 shares of the biotechnology company's stDecember 7 at 3:32 AM | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) shareholders have earned a 34% CAGR over the last five yearsDecember 4, 2024 | finance.yahoo.comJacobs Levy Equity Management Inc. Boosts Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)Jacobs Levy Equity Management Inc. raised its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 40.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,223,781 shares of the biotechnology company's stockDecember 4, 2024 | marketbeat.comCaptrust Financial Advisors Has $4.80 Million Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)Captrust Financial Advisors lowered its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 15.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,740 shareDecember 4, 2024 | marketbeat.comBNP Paribas Financial Markets Has $4.63 Million Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)BNP Paribas Financial Markets cut its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 46.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 100,088 shares of the biotechDecember 4, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 53,191 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)Charles Schwab Investment Management Inc. lifted its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 5.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,026,487 shares of tDecember 2, 2024 | marketbeat.comAlgert Global LLC Increases Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)Algert Global LLC grew its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 216.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 40,115 shares of the biotechnology company's stock after buying an additNovember 28, 2024 | marketbeat.comCorcept Therapeutics: A Most Promising And Compelling BiotechNovember 27, 2024 | seekingalpha.comJoseph Douglas Lyon Sells 1,411 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) StockNovember 27, 2024 | insidertrades.comAlpha DNA Investment Management LLC Invests $464,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT)Alpha DNA Investment Management LLC purchased a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,016 shares of the biotechnologyNovember 25, 2024 | marketbeat.comCerity Partners LLC Trims Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)Cerity Partners LLC trimmed its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 9.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 611,784 shares of the biotechnology company's stockNovember 25, 2024 | marketbeat.comVictory Capital Management Inc. Grows Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Victory Capital Management Inc. grew its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 49.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 41,823 shares of the biotechnology comNovember 25, 2024 | marketbeat.comFY2024 Earnings Estimate for CORT Issued By Zacks ResearchCorcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Stock analysts at Zacks Research upped their FY2024 EPS estimates for Corcept Therapeutics in a research note issued on Wednesday, November 20th. Zacks Research analyst K. Das now forecasts that the biotechnology company will post eaNovember 25, 2024 | marketbeat.comCorcept Shares Rise More Than 60% in Three Months: Here's WhyNovember 22, 2024 | msn.comZacks Research Issues Positive Estimate for CORT EarningsCorcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Zacks Research increased their Q4 2024 earnings estimates for shares of Corcept Therapeutics in a note issued to investors on Wednesday, November 20th. Zacks Research analyst K. Das now anticipates that the biotechnology company willNovember 22, 2024 | marketbeat.comEmpowered Funds LLC Makes New Investment in Corcept Therapeutics Incorporated (NASDAQ:CORT)Empowered Funds LLC acquired a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 38,541 shares of the biotechnologyNovember 21, 2024 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 20.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 859,563 shares of the bNovember 20, 2024 | marketbeat.comCornercap Investment Counsel Inc. Has $426,000 Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Cornercap Investment Counsel Inc. cut its position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 59.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,212 shares of the biotechnology company's stock after selling 13November 17, 2024 | marketbeat.comRoyce & Associates LP Has $16.81 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Royce & Associates LP lifted its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 3.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 363,272 shares of the biotechnolNovember 16, 2024 | marketbeat.comIntellectus Partners LLC Purchases Shares of 54,859 Corcept Therapeutics Incorporated (NASDAQ:CORT)Intellectus Partners LLC acquired a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 54,859 shares of the biotechnology company'sNovember 15, 2024 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Principal Financial Group Inc.Principal Financial Group Inc. lessened its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 4.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 495,658 shares of the biotechnology companyNovember 14, 2024 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Receives Average Rating of "Buy" from AnalystsShares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) have received an average recommendation of "Buy" from the five research firms that are presently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation. The averagNovember 12, 2024 | marketbeat.comVersor Investments LP Buys Shares of 24,800 Corcept Therapeutics Incorporated (NASDAQ:CORT)Versor Investments LP bought a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 24,800 shares of the biotechnology company's stock, valued atNovember 12, 2024 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Stock Holdings Increased by Lisanti Capital Growth LLCLisanti Capital Growth LLC grew its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 79.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 113,155 shares of the bioteNovember 11, 2024 | marketbeat.comCWA Asset Management Group LLC Takes $963,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)CWA Asset Management Group LLC bought a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 20,800 shares of the biotechnology cNovember 11, 2024 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Robeco Institutional Asset Management B.V.Robeco Institutional Asset Management B.V. decreased its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 66.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,436 shares of the biotechnology company's stock afterNovember 11, 2024 | marketbeat.comUS Bancorp DE Raises Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)US Bancorp DE raised its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 162.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,683 shares of the biotechnology company'sNovember 9, 2024 | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) Stock Price Up 8.9% - Time to Buy?Corcept Therapeutics (NASDAQ:CORT) Shares Up 8.9% - Still a Buy?November 8, 2024 | marketbeat.comM&G Plc Takes $11.17 Million Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)M&G Plc acquired a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 242,901 shares of the biotechnology company's stock, valued at approximatelyNovember 8, 2024 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $166,204.18 in StockNovember 6, 2024 | insidertrades.comNew York State Teachers Retirement System Has $5.76 Million Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)New York State Teachers Retirement System decreased its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 12.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investNovember 6, 2024 | marketbeat.comCorcept Stock At New High; Will The Upcoming Regulatory And Clinical Trial Catalysts Take It Higher?November 5, 2024 | markets.businessinsider.comRoman Butler Fullerton & Co. Sells 10,466 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)Roman Butler Fullerton & Co. reduced its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 65.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,565 shares of the biotechnologyNovember 5, 2024 | marketbeat.comTruist Financial Keeps Their Buy Rating on Corcept Therapeutics (CORT)November 4, 2024 | markets.businessinsider.comCorcept Therapeutics (NASDAQ:CORT) Reaches New 1-Year High - Still a Buy?Corcept Therapeutics (NASDAQ:CORT) Reaches New 12-Month High - Here's WhyNovember 4, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for CORT FY2024 Earnings?Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - HC Wainwright increased their FY2024 EPS estimates for shares of Corcept Therapeutics in a report released on Thursday, October 31st. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earningsNovember 4, 2024 | marketbeat.comCorcept Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 3, 2024 | finance.yahoo.comCorcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.2% - Time to Sell?Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.2% - Time to Sell?November 1, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for CORT FY2026 Earnings?Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities research analysts at HC Wainwright boosted their FY2026 EPS estimates for Corcept Therapeutics in a report released on Thursday, October 31st. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology companyNovember 1, 2024 | marketbeat.comCorcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...October 31, 2024 | finance.yahoo.comStrong Financial Performance and Promising Clinical Developments Drive Buy Recommendation for Corcept TherapeuticsOctober 31, 2024 | markets.businessinsider.comCorcept Therapeutics price target raised to $73.50 from $72 at LadenburgOctober 31, 2024 | markets.businessinsider.comCorcept Therapeutics (NASDAQ:CORT) Issues Earnings ResultsCorcept Therapeutics (NASDAQ:CORT - Get Free Report) announced its earnings results on Wednesday. The biotechnology company reported $0.41 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.14. The business had revenue of $182.55 million during the quarter, compared to analysts' expectations of $171.97 million. Corcept Therapeutics had a return on equity of 23.66% and a net margin of 21.93%. The business's revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.28 earnings per share.October 31, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Corcept Therapeutics (NASDAQ:CORT)HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Corcept Therapeutics in a report on Thursday.October 31, 2024 | marketbeat.comCorcept Therapeutics Reports Strong Revenue and Future PlansOctober 31, 2024 | markets.businessinsider.comabrdn plc Grows Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)abrdn plc increased its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 27.1% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 666,952 shares of the biotechnology company's stock after buying an additionalOctober 31, 2024 | marketbeat.comCorcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate UpdateOctober 30, 2024 | businesswire.com Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy. Click to get the name and ticker symbol CORT Media Mentions By Week CORT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CORT News Sentiment▼1.140.69▲Average Medical News Sentiment CORT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CORT Articles This Week▼96▲CORT Articles Average Week Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Royalty Pharma News Today Jazz Pharmaceuticals News Today Perrigo News Today Supernus Pharmaceuticals News Today Pacira BioSciences News Today Omeros News Today Nektar Therapeutics News Today Assembly Biosciences News Today Cumberland Pharmaceuticals News Today Eli Lilly and Company News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CORT) was last updated on 12/8/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredUrgent warning about your moneyThe stock market is booming … And Bitcoin just hiked through the roof. But don't get fooled by the "good...Weiss Ratings | SponsoredWall Street genius says this bubble has run its course – what to doWhile the media is telling you to be excited about the stock market, Wall Street and the market's top experts ...Stansberry Research | SponsoredIs the US economic collapse finally here?Something unsettling is happening to the U.S. economy right now... And it could spell disaster for millions...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CORT Stock Alerts